<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Biomed Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Biomed Sci</journal-id><journal-id journal-id-type="publisher-id">IJBS</journal-id><journal-title-group><journal-title>International Journal of Biomedical Science : IJBS</journal-title></journal-title-group><issn pub-type="ppub">1550-9702</issn><issn pub-type="epub">1555-2810</issn><publisher><publisher-name>Master Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23675010</article-id><article-id pub-id-type="pmc">3614651</article-id><article-id pub-id-type="publisher-id">IJBS-2-414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Intraoperative Ethanol Treatment as an Adjuvant Therapy of Pterygium Excision</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ko-Hua</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Wen-Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan (ROC);</italic></aff><aff id="aff2"><label>2</label><italic>National Yang-Ming University 201, Section II, Shih-Pai Road, Taipei, Taiwan (ROC);</italic></aff><aff id="aff3"><label>3</label><italic>Division of Medical Engineering, National Health Research Institutes. Taipei, Taiwan (ROC)</italic></aff><author-notes><corresp><bold>Corresponding author:</bold> Wen-Ming Hsu, Department of Ophthalmology, Taipei Veterans General Hospital, National Yang-Ming University, 201, Section II, Shih-Pai Road, Taipei, 11217, Taiwan (ROC). Tel: 886-2-28757325; 886-2-28714633; Fax: 886-2-28720959; E-mail: <email xlink:href="khchen@vghtpe.gov.tw">khchen@vghtpe.gov.tw</email>.</corresp><fn><p><bold>Grant:</bold> This research is supported by the grants from: 1. Taipei Veterans General Hospital. (VGH94-120, VGH94-338, VGH94-365-9 and VGHUST94-P1-02); 2. National Health Research Institute (ME-093-CB-#8, NHRI94A1-MEAP01-001); 3. Veterans General Hospitals University System of Taiwan Joint Research Program (VGHUST94-P1-02); 4. National Science Council of Republic of China (NSC91-2320-B-007-007).</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2006</year></pub-date><volume>2</volume><issue>4</issue><fpage>414</fpage><lpage>421</lpage><permissions><copyright-statement>&#x000a9; Ko-Hua Chen <italic>et al.</italic> Licensee Master Publishing Group</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Ko-Hua Chen</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Recurrence of pterygium is the main concern for ophthalmic surgeons after the excision of pterygium. To evaluate the efficacy and safety of ethanol treatment during pterygium excision in preventing the recurrence of pterygia. A prospective randomized study was performed of 78 eyes in primary pterygium patients treated by excision. Primary pterygium patients were randomly assigned to ethanol group (38 eyes given intraoperative ethanol) or mitomycin-c (MMC) group (40 eyes given intraoperative MMC). Ethanol (20%) was applied for 60 seconds to the pterygial and its adjacent corneal surfaces before pterygium excision. After excision, the excised site of sclera was soaked with 20% Ethanol for 60 seconds. In group 2, MMC (0.25 mg/ml) was applied for 60 seconds to the bare sclera after pterygium excision. The outcomes were followed for more than one year. Pterygium recurred in 2 (5.3%) of 38 eyes in ethanol group and 4 (10.0%) of 40 eyes in MMC group. Final appearance of the pterygium excision area was satisfactory in 73.6% of group1 and 67.5% of group 4. No patients experienced severe complications postoperatively. In comparison with MMC treatment, intraoperative ethanol is more efficacious in preventing recurrence of pterygium and causes fewer complications. It suggests this regimen as an alternative for the treatment of pterygium, especially for those patients of high risk group for MMC treatment complications.</p></abstract><kwd-group><kwd>ethanol</kwd><kwd>excision</kwd><kwd>pterygium</kwd><kwd>eecurrence</kwd><kwd>mitomycin</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Pterygia are benign fibrovascular and infiltrative processes of the corneal-conjunctival junctions characterized by a fleshy outgrowth of altered limbal/conjunctival tissue over the cornea. Pterygium can threaten human vision by central corneal invasion. Its high recurrence rate after initial excision is the major concern for ophthalmic surgeons and has lead to numerous methods to alleviate this problem. The bare sclera procedure described by Ombrain (<xref ref-type="bibr" rid="R1">1</xref>) has been practiced worldwide as the most basic technique for pterygium removal. However, the recurrence rate after this procedure is unacceptably high, 30&#x02013;89% (<xref ref-type="bibr" rid="R2">2</xref>-<xref ref-type="bibr" rid="R4">4</xref>). In search of a more effective and safe method for preventing pterygium recurrence after surgical excision, many adjuvant therapies have been investigated such as Sr-90 beta-radiation (<xref ref-type="bibr" rid="R6">6</xref>), soft X-ray irradiation (<xref ref-type="bibr" rid="R7">7</xref>) intraoperative and post-operative mitomycin C (MMC) (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R8">8</xref>-<xref ref-type="bibr" rid="R10">10</xref>), subconjunctival injection of steroid (<xref ref-type="bibr" rid="R11">11</xref>) or 5-fluorouracil (<xref ref-type="bibr" rid="R12">12</xref>), conjunctival or limbal-conjunctival autograft transplantation, (<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>), amniotic membrane transplantation (<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R16">16</xref>), split thickness buccal mucous membrane grafts (<xref ref-type="bibr" rid="R17">17</xref>), and excimer laser treatment (<xref ref-type="bibr" rid="R18">18</xref>). Many possible models of pterygium formation have been proposed, in which immunological reactions (<xref ref-type="bibr" rid="R20">20</xref>-<xref ref-type="bibr" rid="R23">23</xref>), potential oncogenic virus infections (<xref ref-type="bibr" rid="R24">24</xref>-<xref ref-type="bibr" rid="R26">26</xref>), degeneration processes (<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>), ultraviolet irradiation, and neoplastic mechanisms (<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R29">29</xref>) participate in a multi-step process of pterygium pathogenesis. The variation in the theories of pterygium formation implies much about the pathogenesis of pterygium remains to be investigated.</p><p>To minimize the high recurrence rate after pterygium excision, many medications that inhibit cell proliferation (<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref>) have been applied to the excised sites. Intra-operative and post-operative MMC, an antibiotic antineoplastic agent that selectively inhibits the synthesis of DNA, RNA, and protein, were investigated and shown to be useful (<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R8">8</xref>-<xref ref-type="bibr" rid="R10">10</xref>). Intra-operative MMC has gained increasing acceptance in preventing pterygium recurrence (<xref ref-type="bibr" rid="R38">38</xref>) but unfortunately, MMC, a potent inhibitor of cell proliferation with cytotoxicity, caused complications especially in patients of high risk group such as ocular surface disorder and tear dysfunction. Alternative regimens remained to be identified (<xref ref-type="bibr" rid="R38">38</xref>).</p><p>Ethanol has been used widely in medical practice for its anti-microbial properties and also used in treating some tumors such as liver cancers because it causes massive cell apoptosis (<xref ref-type="bibr" rid="R39">39</xref>). Furthermore, it is known to cause in tissues the rapid denaturation of proteins/peptides including cytokines, enzymes, and growth factors that are supposed to be involved in pterygium formation and recurrence after excision. The application of ethanol to the cornea has been done in excimer laser refractory surgeries for around a decade. Low-dose (10&#x02013;30%) ethanol treatment of the corneal epithelium for 20 to 30 seconds during the laser procedures was performed to remove corneal epithelium in photorefractive keratectomy and create corneal epithelial flaps in laser epithelial keratomileusis (LASEK) (<xref ref-type="bibr" rid="R40">40</xref>). It was shown that the application of ethanol at a concentration lower than 20% on the cornea for less than one minute appears to be safe (<xref ref-type="bibr" rid="R53">53</xref>-<xref ref-type="bibr" rid="R55">55</xref>). Most corneal epithelial cells were found to be alive by vital staining after low-dose ethanol treatment and the postoperative wound healing was normal (<xref ref-type="bibr" rid="R41">41</xref>). These studies, therefore, prompted us to conduct a prospective clinical trial to assess the safety and efficacy of intraoperative ethanol (20%) treatment, before and also after pterygium excision, for preventing recurrence. The efficacy of low-dose intraoperative ethanol was compared with that of intraoperative MMC in a historical control group of primary pterygium patients.</p></sec><sec sec-type="methods"><title>PATIENTS AND METHODS</title><p>The protocol of this study was approved by the Institutional Review Board of Taipei Veterans General Hospital and the consent of these patients was obtained before the operations.</p><sec><title>Patient Population</title><p>In the prospective arm of this study, we performed bare sclera pterygium resection in a total of 78 eyes (78 patients) treated consecutively for primary pterygium at the Taipei Veterans General Hospital (Taipei, Taiwan, ROC) between April 2000 and October 2004. Those with small pterygia, &#x0003c;1.5 mm on the cornea, and those with meibomitis, blepharitis, acne rosacea, atopic keratoconjunctivitis, keratoconjunctivitis sicca, Sj&#x000f6;gren&#x02019;s syndrome, or herpes keratitis, or a history of previous ocular surgery, long-term application of ocular medications, or contact lens wear were excluded. Each patient underwent a complete ocular examination, including slit-lamp biomicroscopy and tear film examination.</p><p>To compare the efficacy of intraoperative ethanol and MMC, 38 eyes (38 patients) with primary pterygium (ethanol group) were enrolled randomly for treatment with ethanol and 40 eyes (40 patients) (MMC group) for treatment with MMC. A complete eye examination was performed by one investigator (WM Hsu) before surgery and 1 day, 3 days, 1 week, 10 days, 2 weeks, 1 month, 2 months, 3 months, 6 months and 1 year after surgery. To be included in this study, patients needed to return for all follow-up examinations. Severity of the pterygia was graded according to the extent of corneal encroachment beyond the limbus, as described by Wong V., <italic>et al</italic>. (<xref ref-type="bibr" rid="R43">43</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). The distribution of pterygia by grade is given in Table <xref ref-type="table" rid="T1">1</xref>. Characteristics of patients in each group are shown in Table <xref ref-type="table" rid="T2">2</xref>.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Classification system for pterygia grading. Circle represents cornea; 1, 2, and 3 represent grades of pterygia as they encroach onto cornea beyond the limbus.</p></caption><graphic xlink:href="IJBS-2-414_F1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Number (percentage) of Pterygia Graded by Severity in two Groups</p></caption><table frame="border" rules="none" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Grade 1</th><th rowspan="1" colspan="1">Grade 2</th><th rowspan="1" colspan="1">Grade 3</th><th rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">18 (47.3%)</td><td align="center" rowspan="1" colspan="1">15 (39.5%)</td><td align="center" rowspan="1" colspan="1">5 (13.2%)</td><td align="center" rowspan="1" colspan="1">38</td></tr><tr><td rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">16 (44.4%)</td><td align="center" rowspan="1" colspan="1">13 (36.1%)</td><td align="center" rowspan="1" colspan="1">7 (19.4%)</td><td align="center" rowspan="1" colspan="1">36</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Characteristics of pterigium treatment groups</p></caption><table frame="border" rules="none" width="100%"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Group 1</th><th rowspan="1" colspan="1">Group 2</th><th rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Pterygium</td><td align="center" rowspan="1" colspan="1">Primary</td><td align="center" rowspan="1" colspan="1">Primary</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Adjuvant Therapy</td><td align="center" rowspan="1" colspan="1">Ethanol</td><td align="center" rowspan="1" colspan="1">MMC</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Number of eyes</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age<xref ref-type="table-fn" rid="T2FN1">a</xref> (y)</td><td align="center" rowspan="1" colspan="1">60.8 &#x000b1; 7.8 (45-84)</td><td align="center" rowspan="1" colspan="1">63.1 &#x000b1; 9.0 (48-79)</td><td align="center" rowspan="1" colspan="1">0.18<xref ref-type="table-fn" rid="T2FN2">b</xref></td></tr><tr><td rowspan="1" colspan="1">Gender (% Male)</td><td align="center" rowspan="1" colspan="1">53.3</td><td align="center" rowspan="1" colspan="1">46.6</td><td align="center" rowspan="1" colspan="1">0.96<xref ref-type="table-fn" rid="T2FN3">c</xref></td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><label>a</label><p>Mean &#x000b1; SD (range);</p></fn><fn id="T2FN2"><label>b</label><p>Kruakal-Wallis test;</p></fn><fn id="T2FN3"><label>c</label><p>Chi-square test.</p></fn><fn id="T2FN4"><p>Groups are described in the patients and Methods section. Ethanol, 20% intraoperatively for 60 seconds; MMC, 0.04% mitomycin C intra-operatively for 60 seconds.</p></fn></table-wrap-foot></table-wrap><p>Recurrence of pterygium is usually an early complication after the excision (<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R45">45</xref>) and was almost exclusively noted between post-operative 2-6 months in previous studies (<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R45">45</xref>). In a study by Hirst <italic>et al</italic>. (<xref ref-type="bibr" rid="R46">46</xref>), nearly 50% of recurrences occurred within the first 4 months and nearly all occurred within 1 year of pterygium removal. So all the subjects in this study were followed post-operatively at least for 12 months and we chose a 1-year cutoff period (<xref ref-type="bibr" rid="R47">47</xref>).</p></sec><sec><title>Complete Corneal Epithelial Healing, Grading of Pterygium, the Final Appearance, and Definition of Pterygium Recurrence</title><p>The time needed for complete corneal epithelial healing was recorded and the final appearance of each patient&#x02019;s operated eye was graded by the same investigator (WM Hsu), who was unaware of the group assignment. Corneal epithelium was checked by slit lamp microscope at every follow-up visit, and negative fluorescein staining of the cornea was defined as complete corneal epithelial healing.</p><p>Final appearance was checked by review of the last available photograph of the eyes using the criteria described by Prabhasawat <italic>et al</italic>. (<xref ref-type="bibr" rid="R48">48</xref>) In brief, a grade 1 result denoted the indistinguishability of the operated eye from normal; grade 2 was indicated by the presence of some fine episcleral vessels in the excised area extending up to the limbus but not beyond, in the absence of any fibrous tissue; grade 3, by the presence of additional fibrous tissues in the excised area without invasion into the cornea; and grade 4, by the true recurrence of pterygium with fibrovascular tissue invading a clear cornea. Pterygium recurrence rates, grade 4, are based on the results of the latest follow-up examination. Patients with grades 1 or 2 as their final results of pterygium excision were generally pleased with the postoperative appearance of their eyes.</p></sec><sec><title>Surgical Techniques</title><p>All surgical procedures were performed by one surgeon (K. H. Chen) to ensure consistency in surgical methods. The procedure of ethanol application was modified from the LASEK method originally described by Massino Camellin, MD (M. Cimberele, &#x0201c;LASEK Has More Than 1 Year of Successful Experience&#x0201d;, Ocular Surgery News, July 15, 2000, pp. 14-17). The methods of MMC treatment were the same as those described by Wong VA <italic>et al</italic>. (<xref ref-type="bibr" rid="R43">43</xref>) Preparations for the surgery and the technique for pterygium excision were the same in all cases. All eyes were treated as follows (Figure <xref ref-type="fig" rid="F2">2</xref>):
<list list-type="bullet"><list-item><p>The ocular surface was anesthetized with 4 to 5 drops of topical 2% lidocaine (Xylocaine; Fujisawa Pharmaceutical, Osaka, Japan) in the preoperative holding area.</p></list-item><list-item><p>After the eye was prepared with povidone-iodine (Betadine) and a plastic drape and lid speculum were placed, the pterygium was insufflated with a 2% lidocaine/1:100,000 epinephrine mixture to separate it from the underlying sclera.</p></list-item><list-item><p>A Westcott scissors was used to separate the body of the pterygium (the scleral part of pterygium) from the surrounding conjunctiva, leaving the corneal part of pterygium attached on three sides.</p></list-item><list-item><p>In the ethanol treatment group, an optical zone marker (model E9011 3.0:storz. St. Louis, MO) of adequate size was used to delineate the area for corneal epithelium/pterygium removal (Figure <xref ref-type="fig" rid="F2">2A</xref>). The size of the optical zone marker was determined by three points: point A and B, the pterygium margins at limbus, and a third point, C, located 1 to 1.5 mm (Figure <xref ref-type="fig" rid="F3">3</xref>).</p></list-item><list-item><p>The barrel of the optical zone marker was filled with two drops of 20% ethanol. The dehydrated alcohol (1-ml ampoules; American Reagent Laboratories, Inc. Shirley. NY) was diluted in balanced salt solution and an ampoule opened fresh every treatment session. After 60 seconds, the ethanol was absorbed using a cellulose sponge (Medtronic Xomed, Jacksonville, FL) (Figure <xref ref-type="fig" rid="F2">2B</xref>).</p></list-item><list-item><p>The loosened epithelium was lifted and removed, usually as a single sheet, with another dry cellulose sponge toward the pterygium site (Figure <xref ref-type="fig" rid="F2">2C</xref>).</p></list-item><list-item><p>The adherence of the pterygium body was dissected and separated with a Beaver 64 surgical blade (Becton Dickinson, Franklin Lakes, NJ) and usually the epithelium/pterygium complex could be totally detached from the cornea together when the dissection reached the limbus.</p></list-item><list-item><p>A Westcott scissors was used for complete circumcision of the conjunctiva along the mark (Figure <xref ref-type="fig" rid="F2">2E</xref>). Blunt dissection was used to free and resect the conjunctiva and Tenon&#x02019;s capsule and fibrous tissue completely, leaving the bare sclera (Figure <xref ref-type="fig" rid="F2">2F</xref>) exposed. Complete removal of residual pterygium tissue was confirmed by the exposure of all episcleral blood vessels. Residual abnormal or scarred tissue on the corneal surface was scraped off with the same Beaver 64 surgical blade.</p></list-item><list-item><p>In Ethanol group, at the completion of pterygium excision, 9 pieces of 5 &#x000d7; 5 mm Merocel sponge (Merocel Corp., Mystic, CT) supersaturated with 20% ethanol was applied to the bare scleral bed for 60 seconds followed by light irrigation with a 15-ml bottle of balanced salt solution (BSS).</p></list-item><list-item><p>In MMC group, without any application of intraoperative ethanol, at the completion of pterygium excision, a 7 &#x000d7; 7 mm Merocel sponge (Merocel Corp., Mystic, CT) supersaturated with MMC (0.25 mg/mL; Kyowa Hakko Kogyo Co., Tokyo, Japan) was applied to the bare scleral bed for 60 seconds followed by light irrigation with BSS.</p></list-item><list-item><p>No sutures were placed to approximate the excised edges of the conjunctiva in any patient.</p></list-item><list-item><p>At the completion of the surgery in all groups, one drop of 0.3% gentamicin was applied topically to each operated eye and the eye was patched for 1 day.</p></list-item></list>
</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Technique for pterygium excision with intraoperative application of ethanol as an adjuvant. (A). Application of 20% ethanol in a ring marker. (B). Removal of the marker after absorbing the ethanol with a cellulose sponge. (C). Lifting the margin of epithelial flap with two cellulose sponges. (D). Dissecting the adherence of the pterygium body and separating with a Beaver 64 surgical blade. (E). Circumcising completely the conjunctival part of pterygium using a Westcott scissors along the mark. (F) A bare sclera after complete removal of residual pterygium tissue.</p></caption><graphic xlink:href="IJBS-2-414_F2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Determination of the adequate size of the optical zone marker. A optical zone marker (model E9011 3.0:storz. St. Louis, MO) of adequate size was used to delineate the area for corneal epithelium/pterygium removal. The size of the optical zone marker was determined by three points: point A and B, the pterium margins at limbus, and a third point, C, located 1 mm (in the case of primary pterygium) or 2 mm (in the case of recurrent pterygium) central to the head of pterygium.</p></caption><graphic xlink:href="IJBS-2-414_F3"/></fig><p>Postoperatively, all eyes were treated with topical dexamethasone (Maxidex; Alcon, Puurs, Belgium) alone four times a day for 1 week, followed by tapered dosages until cessation of treatment at the end of the fourth week after surgery.</p></sec><sec><title>Statistical Analysis</title><p>Student&#x02019;s t-tests, Mann-Whitney U tests, Kruskal-Wallis tests and chi-square tests were used to compare groups. Fisher&#x02019;s exact test was used to compare epithelial healing time, complication and recurrence rates between groups. The null hypothesis was rejected if the p value was &#x0003c;0.05. A StatView statistical software package (Abacus Concepts, Berkeley, CA) was used to analyze the data.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>All the patients in this study were Chinese and from Taiwan. The distribution of pterygia by grade is given in Table <xref ref-type="table" rid="T1">1</xref>, and no statistical difference in grade was found between ethanol group and MMC treatment group (<italic>p</italic>&#x0003e;0.1). As Table <xref ref-type="table" rid="T2">2</xref> shows, there were no statistically significant differences in age or gender distribution among these four groups (<italic>p</italic>=0.18 and 0.96, respectively). The mean follow-up period for all groups in this study was 14.8 &#x000b1; 3.8 months. (range, 12-20 months)</p><sec><title>Recurrence Rate</title><p>The recurrence rates of pterygium after excision were higher in the group treated with MMC than ethanol. Pterygium recurred within 1-12 months after surgery in 1 (2.6%) of 38 eyes of ethanol group and in 4 (10.0%) of 40 eyes of MMC group. But, using Fisher&#x02019;s exact test, there was no significant difference (<italic>p</italic>=0.16) between patients in the ethanol treatment group and in the MMC treatment group.</p><p>The time to detection of pterygium recurrence after surgery in this study ranged between 2 and 12 months (3.7 &#x000b1; 3.6 months) overall and was 3.0, 4.1 &#x000b1; 1.7, 3.9 &#x000b1; 2.1, and 4.5 &#x000b1; 3.5 months for groups 1 and 2. There was also no difference between the two groups (<italic>p</italic>=0.32).</p></sec><sec><title>Complete Corneal Epithelial Healing</title><p>The durations for complete corneal epithelial healing after surgeries are shown in Table <xref ref-type="table" rid="T3">3</xref>. The time needed for epithelial healing was shorter in ethanol group (<italic>p</italic>&#x0003c;0.05), compared to that needed for healing of patients treated with MMC.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Final outcome of 1ntraoperative ethanol and MMC for primary pterygia</p></caption><table frame="border" rules="none" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Group 1</th><th rowspan="1" colspan="1">Group 2</th><th rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Follow up (Mo)<xref ref-type="table-fn" rid="T3FN1">a</xref></td><td align="center" rowspan="1" colspan="1">15.3 &#x000b1; 2.3 (12--18)</td><td align="center" rowspan="1" colspan="1">13.5 &#x000b1; 3.3 (12--19)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Time for complete corneal epithelial heal (days)<xref ref-type="table-fn" rid="T3FN1">a</xref></td><td align="center" rowspan="1" colspan="1">3.3 &#x000b1; 0.2 (3-5)</td><td align="center" rowspan="1" colspan="1">7.1 &#x000b1; 1.7 (6-11)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td rowspan="1" colspan="1">Grading of final appearance</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;1</td><td align="center" rowspan="1" colspan="1">13/38 (34.2%)</td><td align="center" rowspan="1" colspan="1">7/40 (17.5%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;2</td><td align="center" rowspan="1" colspan="1">15/38 (39.4%)</td><td align="center" rowspan="1" colspan="1">20/40 (50.0%)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;3</td><td align="center" rowspan="1" colspan="1">9/38 (23.7%)</td><td align="center" rowspan="1" colspan="1">9/40 (22.5%)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;4 (=Recurrence rate, number)
</td><td align="center" rowspan="1" colspan="1">1/38 (2.6%)</td><td align="center" rowspan="1" colspan="1">4/40 (10.0%)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn id="T3FN1"><label>a</label><p>Mean &#x000b1; SD (range).</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Final Appearance</title><p>Table <xref ref-type="table" rid="T3">3</xref> showed of three-quarters of those who received ethanol (73.6%) had final appearances that were classified either as grade 1 or 2 (i.e., appearance generally acceptable to both the patient and the physician), whereas around two-thirds of patients who underwent MMC treatment (67.5%) received a grade 1 or 2. The difference in the proportion of patients with cosmetically acceptable final appearance between the two groups was not statistically significant (<italic>p</italic>=0.56).</p></sec><sec><title>Complications</title><p>As shown in Table <xref ref-type="table" rid="T4">4</xref>, no complication was found in both groups treated with intraoperative ethanol, and 16.6% complication rates were found in MMC-treated group. Superficial punctate keratitis was the most common complication in each of the MMC-treated group. Other minor complications included granuloma and dellen formation noted during the first and second week after bare sclera excision with intraoperative MMC. Throughout postoperative follow-up time, there were no severe complications, such as scleral necrosis, in any patients of this study.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Complications of Intraoperative ethanol and MMC for primary pterygium</p></caption><table frame="border" rules="none" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Group 1 (n=38)</th><th rowspan="1" colspan="1">Group 2 (n=36)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Superficial punctatate keratitis</td><td align="center" rowspan="1" colspan="1">0/38</td><td align="center" rowspan="1" colspan="1">5/36 (13.6%)</td></tr><tr><td rowspan="1" colspan="1">Conjunctival granuloma</td><td align="center" rowspan="1" colspan="1">0/38</td><td align="center" rowspan="1" colspan="1">1/36 (2.7%)</td></tr><tr><td rowspan="1" colspan="1">Formation of dellen</td><td align="center" rowspan="1" colspan="1">0/38</td><td align="center" rowspan="1" colspan="1">1/36 (2.7%)</td></tr><tr><td rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">0/38 (0%)</td><td align="center" rowspan="1" colspan="1">6/36 (16.7%)</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study we have demonstrated the superiority of intraoperative ethanol compared to intraoperative MMC as an adjuvant therapy of pterygium excision in preventing recurrence. During a follow-up for a minimum of 12 months, we found there were no complications due to intraoperative 20% ethanol application. The recurrence rates of intraoperative MMC treatment (concentrations of 0.02-0.04% for 1-5 minutes) ranged from 3.3 to 42.9% in primary pterygium patients (<xref ref-type="bibr" rid="R49">49</xref>-<xref ref-type="bibr" rid="R52">52</xref>) and our data (0.025% for 1 minute) showed a recurrence rate of 11.1%.</p><p>In the past decade, mounting evidence has implied that many factors are involved in the process of pterygium formation including the UV-induced inflammatory cytokines (<xref ref-type="bibr" rid="R30">30</xref>), growth factors (<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R31">31</xref>-<xref ref-type="bibr" rid="R34">34</xref>) and proteolytic enzymes like matrix metalloproteinases and their inhibitors. (<xref ref-type="bibr" rid="R35">35</xref>) These factors could be secreted by cells of pterygium tissues, blood vessels, leukocytes and pterygium-adjacent corneal cells and closely related to the high recurrence rate of pterygium after surgical excision (<xref ref-type="bibr" rid="R30">30</xref>-<xref ref-type="bibr" rid="R35">35</xref>). These data suggest that therapy of alleviating these factors could possibly act as an adjuvant of surgical excision to prevent recurrence and we have demonstrated 20% ethanol is safe and effective. Though the difference was not significant, the complication rate is lower and corneal epithelial healing is faster in ethanol treatment group (<italic>P</italic>&#x0003c;0.05). Furthermore, an advantage of ethanol treatment is the underling stromal smoothness. As the electron microscope studies of LASEK (<xref ref-type="bibr" rid="R58">58</xref>), ethanol delamination of the pterygium/corneal epithelium results in a very smooth cleavage at the level of the pterygium/stromal attachments. (Figure <xref ref-type="fig" rid="F3">3</xref>) It leaves behind a very smooth surface, which is ideal for epithilaization.</p><p>Though the histological and pathological changes of pterygial tissues have been well studied, almost all of the documented specimens did not include the adjacent tissues. Seifert P et al. have demonstrated that the corneal tissues adjacent to the pterygial protuberance were histologically altered (<xref ref-type="bibr" rid="R53">53</xref>) It has been proposed that pterygia recur because of the incomplete removal of altered limbal cells that have invaded basal corneal, conjunctival, and circumferential limbal epithelia. (<xref ref-type="bibr" rid="R29">29</xref>) It follows that if all the histologically abnormal tissues (including ptergium and pterygium-adjacent tissues) are removed, the rate of recurrence will be reduced (<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R54">54</xref>). But in practice, for ophthalmologic surgeons it is hazardous to excise ocular tissues extensively for a benign lesion like pterygium because severe or vision-threatening complications such as corneal ectasia/perforation, post-operative astigmatism and corneal/scleral ulcers could result. By our data, the extended range, 1-1.5 mm central to the head of pterygium (Figure <xref ref-type="fig" rid="F3">3</xref>) and the surgical area, of 20% ethanol application could possibly be an effective method to alleviate the possible factors in pterygium-adjacent tissues that are highly related to recurrence.</p><p>Compatible with the reports on LASEK, no complications of low-dose ethanol treatment in our study were noted during the more than one year of follow-up. Though it was shown that after 20% ethanol treatment of the cornea for less than one minute, most epithelial cells were found alive (<xref ref-type="bibr" rid="R41">41</xref>), the occurrence of widespread partial or total damage of microvilli, focal breaks of intercellular junction, and cellular edema was observed by microscopy. (<xref ref-type="bibr" rid="R57">57</xref>) Others have observed no corneal complications in all the patients treated with ethanol of similar concentrations, 18 to 20%, for shorter durations, 30 to 45 seconds, in LASEK (<xref ref-type="bibr" rid="R53">53</xref>-<xref ref-type="bibr" rid="R55">55</xref>). On the basis of these findings, we have strong reasons to believe intraoperative low-dose ethanol application for one minute is safe, but more cases and a longer follow-up time are needed to achieve a solid conclusion. Therefore, we recommend a large-scale, randomized, controlled study of various dosage regimens to elucidate the optimal dosage and long-term safety profile of intra-operative ethanol.</p><p>On the contrary, toxicity of MMC is well-documented and can possibly manifest through vision-threatening complications such as scleral ulceration, corneal perforation, secondary glaucoma, and complicated cataract to minor side effects such as low-grade ocular pain, photophobia, superficial punctate keratitis and delayed conjunctival wound healing. (<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R56">56</xref>) Intraoperative MMC delivery involves a direct sclera bed application of MMC that could possibly be a risk factor predisposing to the scleral ulcer. By our observations in the current study, we also found a significant longer time duration for corneal epithelial healing in MMC treatment group. During the 14-month mean follow-up of MMC group, we noted only early, minor side effects and no serious complications. This is probably due to the lower MMC concentration and shorter dose duration we adopted. (<xref ref-type="bibr" rid="R8">8</xref>)</p><p>In conclusion, the results of our study demonstrated that ethanol administered over a very short time interval intraoperatively (20% ethanol for 60 seconds) is a safe and effective way to reduce the pterygium recurrence rate after excision of pterygium. In the current study, the low pterygium recurrence rate, the high level of cosmetic satisfaction, the simplicity of the procedure, the minimal risk of minor side effects, and the lack of major complications after treatment lead us to recommend this regimen as an alternative for the treatment of pterygium, especially for those patients of high risk group for MMC treatment.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ombrain</surname><given-names>A</given-names></name></person-group><article-title>The surgical treatment of pterygium</article-title><source>Br. J. Ophthalmol</source><year>1948</year><volume>32</volume><fpage>65</fpage><pub-id pub-id-type="pmid">18170420</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaros</surname><given-names>PA</given-names></name><name><surname>DeLuise</surname><given-names>VP</given-names></name></person-group><article-title>Pingueculae and pterygia</article-title><source>Surv. Ophthalmol</source><year>1988</year><volume>33</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">3051468</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name></person-group><article-title>Mitomycin eye drops as treatment for pterygium</article-title><source>Ophthalmology</source><year>1988</year><volume>95</volume><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">3211484</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Ariyasu</surname><given-names>RG</given-names></name><name><surname>Kaza</surname><given-names>V</given-names></name><name><surname>LaBree</surname><given-names>LD</given-names></name><etal/></person-group><article-title>A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium</article-title><source>Am. J. Ophthalmol</source><year>1995</year><volume>120</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">7639298</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helal</surname><given-names>M</given-names></name><name><surname>Messiha</surname><given-names>N</given-names></name><name><surname>Amayem</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intraoperative mitomycin C versus postoperative topical mitomycin C drops for the treatment of pterygium</article-title><source>Ophthalmic. Surg. Lasers</source><year>1996</year><volume>27</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">8858633</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Dzugan</surname><given-names>SA</given-names></name><name><surname>Kosko</surname><given-names>P</given-names></name></person-group><article-title>Postoperative beta irradiation for control of pterygium</article-title><source>J. Miss. State. Med. Assoc</source><year>2001</year><volume>42</volume><fpage>167</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">11433925</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willner</surname><given-names>J</given-names></name><name><surname>Flentje</surname><given-names>M</given-names></name><name><surname>Lieb</surname><given-names>W</given-names></name></person-group><article-title>Soft X-ray therapy of recurrent pterygium--an alternative to 90Sr eye applicators</article-title><source>Strahlenther. Onkol</source><year>2001</year><volume>177</volume><fpage>404</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">11544903</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>HC</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Kao</surname><given-names>PL</given-names></name><name><surname>Chen</surname><given-names>FK</given-names></name></person-group><article-title>Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery</article-title><source>Cornea</source><year>2001</year><volume>20</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11188998</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Ram</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name></person-group><article-title>Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up</article-title><source>Ophthalmic. Surg. Lasers</source><year>2000</year><volume>31</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">10928667</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Fan</surname><given-names>DS</given-names></name><name><surname>Chew</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>901</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">9593395</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mypet</surname><given-names>C</given-names></name><name><surname>Oko</surname><given-names>H</given-names></name></person-group><article-title>Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium</article-title><source>Cent. Afr. J. Med</source><year>2000</year><volume>46</volume><fpage>330</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">11486474</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pikkel</surname><given-names>J</given-names></name><name><surname>Porges</surname><given-names>Y</given-names></name><name><surname>Ophir</surname><given-names>A</given-names></name></person-group><article-title>Halting pterygium recurrence by postoperative 5-fluorouracil</article-title><source>Cornea</source><year>2001</year><volume>20</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">11248822</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jap</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>DT</given-names></name></person-group><article-title>Conjunctival rotation autograft for pterygium. An alternative to conjunctival autografting</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9917783</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekaris</surname><given-names>I</given-names></name><name><surname>Gabric</surname><given-names>N</given-names></name><name><surname>Karaman</surname><given-names>Z</given-names></name><name><surname>Mravicic</surname><given-names>I</given-names></name><etal/></person-group><article-title>Pterygium treatment with limbal-conjunctival autograft transplantation</article-title><source>Coll. Antropol</source><year>2001</year><issue>25 Suppl</issue><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11817018</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekin</surname><given-names>NF</given-names></name><name><surname>Kaynak</surname><given-names>S</given-names></name><name><surname>Saatci</surname><given-names>AO</given-names></name><name><surname>Cingil</surname><given-names>G</given-names></name></person-group><article-title>Preserved human amniotic membrane transplantation in the treatment of primary pterygium</article-title><source>Ophthalmic. Surg. Lasers</source><year>2001</year><volume>32</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">11725769</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Pires</surname><given-names>RT</given-names></name><name><surname>Tseng</surname><given-names>SC</given-names></name></person-group><article-title>Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>449</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">11237898</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Collin</surname><given-names>R</given-names></name><name><surname>Dart</surname><given-names>J</given-names></name></person-group><article-title>Split thickness buccal mucous membrane grafts and beta irradiation in the treatment of recurrent pterygium</article-title><source>Br. J. Ophthalmol</source><year>1998</year><volume>82</volume><fpage>1420</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">9930275</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>T</given-names></name><name><surname>Schnelle</surname><given-names>B</given-names></name><name><surname>Wollensak</surname><given-names>J</given-names></name></person-group><article-title>Pterygium excision using 193-nm excimer laser smoothing and topical mitomycin C</article-title><source>Ger. J. Ophthalmol</source><year>1992</year><volume>1</volume><fpage>429</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">1490143</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dushku</surname><given-names>N</given-names></name><name><surname>Hatcher</surname><given-names>SL</given-names></name><name><surname>Albert</surname><given-names>DM</given-names></name><name><surname>Reid</surname><given-names>TW</given-names></name></person-group><article-title>p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors</article-title><source>Arch. Ophthalmol</source><year>1999</year><volume>117</volume><fpage>1593</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">10604662</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raizada</surname><given-names>IN</given-names></name><name><surname>Bhatnagar</surname><given-names>NK</given-names></name></person-group><article-title>Pinguecula and pterygium (a histopathological study)</article-title><source>Indian J. Ophthalmol</source><year>1976</year><volume>24</volume><fpage>16</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1031388</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WW</given-names></name></person-group><article-title>A hypothesis on the pathogenesis of pterygiums</article-title><source>Ann. Ophthalmol</source><year>1978</year><volume>10</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">350121</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Zucca</surname><given-names>I</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><etal/></person-group><article-title>Immunohistochemical study of human pterygium</article-title><source>Histol. Histopathol</source><year>2002</year><volume>17</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">11813864</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Okisaka</surname><given-names>S</given-names></name><name><surname>Ebihara</surname><given-names>N</given-names></name></person-group><article-title>Pterygium and mast cells--mast cell number, phenotype, and localization of stem cell factor</article-title><source>Nippon. Ganka. Gakkai. Zasshi</source><year>1997</year><volume>101</volume><fpage>662</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">9284622</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detorakis</surname><given-names>ET</given-names></name><name><surname>Sourvinos</surname><given-names>G</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name></person-group><article-title>Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium</article-title><source>Cornea</source><year>2001</year><volume>20</volume><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">11248821</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>MJ</given-names></name><name><surname>Giannoudis</surname><given-names>A</given-names></name><name><surname>Herrington</surname><given-names>CS</given-names></name><name><surname>Hiscott</surname><given-names>P</given-names></name></person-group><article-title>Human papillomavirus in pterygium</article-title><source>Br. J. Ophthalmol</source><year>2001</year><volume>85</volume><fpage>782</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">11423447</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cilova-Atanasova</surname><given-names>B</given-names></name></person-group><article-title>On the pathogenesis of pterygium</article-title><source>Folia Med. (Plovdiv)</source><year>1971</year><volume>13</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">4999714</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>P</given-names></name><name><surname>Jakobiec</surname><given-names>FA</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Hornblass</surname><given-names>A</given-names></name></person-group><article-title>Elastofibroma oculi</article-title><source>Arch. Ophthalmol</source><year>1983</year><volume>101</volume><fpage>1575</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">6626014</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Sourvinos</surname><given-names>G</given-names></name><name><surname>Kiaris</surname><given-names>H</given-names></name><name><surname>Tsamparlakis</surname><given-names>J</given-names></name></person-group><article-title>Microsatellite instability and loss of heterozygosity in human pterygia</article-title><source>Br. J. Ophthalmol</source><year>1997</year><volume>81</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">9274415</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dushku</surname><given-names>N</given-names></name><name><surname>Hatcher</surname><given-names>SL</given-names></name><name><surname>Albert</surname><given-names>DM</given-names></name><name><surname>Reid</surname><given-names>TW</given-names></name></person-group><article-title>p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors</article-title><source>Arch. Ophthalmol</source><year>1999</year><volume>117</volume><fpage>1593</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">10604662</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Harten</surname><given-names>B</given-names></name><etal/></person-group><article-title>Ultraviolet irradiation induces the production of multiple cytokines by human corneal cells</article-title><source>Invest Ophthalmol. Vis. Sci</source><year>1997</year><volume>38</volume><fpage>2483</fpage><lpage>2491</lpage><pub-id pub-id-type="pmid">9375566</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kria</surname><given-names>L</given-names></name><name><surname>Ohira</surname><given-names>A</given-names></name><name><surname>Amemiya</surname><given-names>T</given-names></name></person-group><article-title>Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium</article-title><source>Acta. Histochem</source><year>1996</year><volume>98</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">8739304</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>I</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Okisaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of stem cell factor in pterygium</article-title><source>J. Ophthalmol</source><year>2000</year><volume>44</volume><fpage>193</fpage><lpage>197</lpage></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia</article-title><source>Cornea</source><year>2001</year><volume>20</volume><fpage>738</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">11588427</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maini</surname><given-names>R</given-names></name><name><surname>Collison</surname><given-names>DJ</given-names></name><name><surname>Maidment</surname><given-names>JM</given-names></name><name><surname>Davies</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Pterygial derived fibroblasts express functionally active histamine and epidermal growth factor receptors</article-title><source>Exp. Eye Res</source><year>2002</year><volume>74</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">11950234</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Girolamo</surname><given-names>N</given-names></name><name><surname>McCluskey</surname><given-names>P</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Coroneo</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells</article-title><source>Invest Ophthalmol. Vis. Sci</source><year>2000</year><volume>41</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">10711680</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ti</surname><given-names>SE</given-names></name><name><surname>Tseng</surname><given-names>SC</given-names></name></person-group><article-title>Management of primary and recurrent pterygium using amniotic membrane transplantation</article-title><source>Curr. Opin. Ophthalmol</source><year>2002</year><volume>13</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">12165701</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The PCNA immunohistochemical study of pterygium</article-title><source>Chung Hua Yen Ko Tsa Chih</source><year>1999</year><volume>35</volume><fpage>380</fpage><lpage>382</lpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>BD</given-names></name></person-group><article-title>Prevention of pterygium recurrence: conjunctival grafts vs. mitomycin C</article-title><source>Can. J. Ophthalmol</source><year>1995</year><volume>30</volume><fpage>115</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">7627894</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanji</surname><given-names>AA</given-names></name></person-group><article-title>Apoptosis and alcoholic liver disease</article-title><source>Semin. Liver Dis</source><year>1998</year><volume>18</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">9606815</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scerrati</surname><given-names>E</given-names></name></person-group><article-title>Laser in situ keratomileusis vs. laser epithelial keratomileusis (LASIK vs. LASEK)</article-title><source>J. Refract. Surg</source><year>2001</year><volume>17</volume><issue>2 Suppl</issue><fpage>S219</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">11316025</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreiss</surname><given-names>AK</given-names></name><name><surname>Winkler Von Mohrenfels</surname><given-names>C</given-names></name><name><surname>Gabler</surname><given-names>B</given-names></name><name><surname>Kohnen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Laser epithelial keratomileusis (LASEK): histological investigation for vitality of corneal epithelial cells after alcohol exposure</article-title><source>Klin. Monatsbl. Augenheilkd</source><year>2002</year><volume>219</volume><fpage>365</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">12094319</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Fayez</surname><given-names>MF</given-names></name></person-group><article-title>Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>1752</fpage><lpage>1755</lpage><pub-id pub-id-type="pmid">12208727</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VA</given-names></name><name><surname>Law</surname><given-names>FC</given-names></name></person-group><article-title>Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>1512</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">10442896</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayasaka</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>SN</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium</article-title><source>Am. J. Ophthalmol</source><year>1988</year><volume>106</volume><fpage>715</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">3143266</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cano-Parra</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>LM</given-names></name><name><surname>Maldonado</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium</article-title><source>Br. J. Ophthalmol</source><year>1995</year><volume>79</volume><fpage>439</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">7612555</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirst</surname><given-names>LW</given-names></name><name><surname>Sebban</surname><given-names>A</given-names></name><name><surname>Chant</surname><given-names>D</given-names></name></person-group><article-title>Pterygium recurrence time</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>755</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">8152771</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewallen</surname><given-names>S</given-names></name></person-group><article-title>A randomized trial of conjunctival autografting for pterygium in the tropics</article-title><source>Ophthalmology</source><year>1989</year><volume>96</volume><fpage>1612</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">2694049</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhasawat</surname><given-names>P</given-names></name><name><surname>Barton</surname><given-names>K</given-names></name><name><surname>Burkett</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of conjunctival autograft, amniotic membrane graft, and primary closure for pterygium excision</article-title><source>Ophthalmology</source><year>1997</year><volume>104</volume><fpage>974</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">9186439</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caliskan</surname><given-names>S</given-names></name><name><surname>Orhan</surname><given-names>M</given-names></name><name><surname>Irkec</surname><given-names>M</given-names></name></person-group><article-title>Intraoperative and postoperative use of mitomycin C in the treatment of primary pterygium</article-title><source>Ophthalmic. Surg. Lasers</source><year>1996</year><volume>27</volume><fpage>600</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">9240777</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frucht-Pery</surname><given-names>J</given-names></name><name><surname>Ilsar</surname><given-names>M</given-names></name><name><surname>Herne</surname><given-names>I</given-names></name></person-group><article-title>Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report</article-title><source>Cornea</source><year>1994</year><volume>13</volume><fpage>411</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">7995063</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastropasqua</surname><given-names>L</given-names></name><name><surname>Carpineto</surname><given-names>P</given-names></name><name><surname>Ciancaglini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium</article-title><source>Br. J. Ophthalmol</source><year>1996</year><volume>80</volume><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">8703875</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frucht-Pery</surname><given-names>J</given-names></name><name><surname>Siganos</surname><given-names>CS</given-names></name><name><surname>Ilsar</surname><given-names>M</given-names></name></person-group><article-title>Intraoperative application of topical mitomycin C for pterygium surgery</article-title><source>Ophthalmology</source><year>1996</year><volume>103</volume><fpage>674</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">8618770</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>P</given-names></name><name><surname>Eckert</surname><given-names>J</given-names></name><name><surname>Spitznas</surname><given-names>M</given-names></name></person-group><article-title>Topological-histological investigation of the pterygium</article-title><source>Graefes. Arch. Clin. Exp. Ophthalmol</source><year>2001</year><volume>239</volume><fpage>288</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">11450493</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>DQ</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Tseng</surname><given-names>SC</given-names></name></person-group><article-title>Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines</article-title><source>Invest Ophthalmol. Vis. Sci</source><year>2000</year><volume>41</volume><fpage>2154</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">10892857</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugar</surname><given-names>A</given-names></name></person-group><article-title>Who should receive mitomycin C after pterygium surgery? (Editorial)</article-title><source>Ophthalmology</source><year>1989</year><volume>96</volume><fpage>1612</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">2694049</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougherty</surname><given-names>PJ</given-names></name><name><surname>Hardten</surname><given-names>DR</given-names></name><name><surname>Lindstrom</surname><given-names>RL</given-names></name></person-group><article-title>Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C</article-title><source>Cornea</source><year>1996</year><volume>15</volume><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">8862932</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Sah</surname><given-names>WJ</given-names></name><name><surname>Lim</surname><given-names>YW</given-names></name><name><surname>Hahn</surname><given-names>TW</given-names></name></person-group><article-title>Twenty percent alcohol toxicity on rabbit corneal epithelial cells: electron microscopic study</article-title><source>Cornea</source><year>2002</year><volume>21</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">11973388</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>AC</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Dua</surname><given-names>HS</given-names></name><name><surname>Maharajan</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Alcohol debridement of the corneal epithelium in PRK and LASEK: an electron microscopic study</article-title><source>Invest Ophthalmo. Vis. Sci</source><year>2003</year><volume>44</volume><issue>2</issue><fpage>510</fpage><lpage>513</lpage></element-citation></ref></ref-list></back></article>